183 related articles for article (PubMed ID: 15618202)
21. Shiga toxin activatable by intestinal mucus in Escherichia coli isolated from humans: predictor for a severe clinical outcome.
Bielaszewska M; Friedrich AW; Aldick T; Schürk-Bulgrin R; Karch H
Clin Infect Dis; 2006 Nov; 43(9):1160-7. PubMed ID: 17029135
[TBL] [Abstract][Full Text] [Related]
22. Prevalence, virulence profiles, and clinical significance of Shiga toxin-negative variants of enterohemorrhagic Escherichia coli O157 infection in humans.
Friedrich AW; Zhang W; Bielaszewska M; Mellmann A; Köck R; Fruth A; Tschäpe H; Karch H
Clin Infect Dis; 2007 Jul; 45(1):39-45. PubMed ID: 17554698
[TBL] [Abstract][Full Text] [Related]
23. Uncommon Shiga toxin-producing Escherichia coli serotype O165:HNM as cause of hemolytic uremic syndrome in São Paulo, Brazil.
de Souza RL; Nishimura LS; Guth BE
Diagn Microbiol Infect Dis; 2007 Oct; 59(2):223-5. PubMed ID: 17662558
[TBL] [Abstract][Full Text] [Related]
24. Assessment in mice of the therapeutic potential of tailored, multivalent Shiga toxin carbohydrate ligands.
Mulvey GL; Marcato P; Kitov PI; Sadowska J; Bundle DR; Armstrong GD
J Infect Dis; 2003 Feb; 187(4):640-9. PubMed ID: 12599081
[TBL] [Abstract][Full Text] [Related]
25. Shiga toxin-producing Escherichia coli and their bacteriophages as a model for the analysis of virulence and stress response of a food-borne pathogen.
Creuzburg K; Schmidt H
Berl Munch Tierarztl Wochenschr; 2007; 120(7-8):288-95. PubMed ID: 17715821
[TBL] [Abstract][Full Text] [Related]
26. Intracerebroventricular Shiga toxin 2 increases the expression of its receptor globotriaosylceramide and causes dendritic abnormalities.
Tironi-Farinati C; Loidl CF; Boccoli J; Parma Y; Fernandez-Miyakawa ME; Goldstein J
J Neuroimmunol; 2010 May; 222(1-2):48-61. PubMed ID: 20347160
[TBL] [Abstract][Full Text] [Related]
27. Shiga toxin-glycosphingolipid interaction: Status quo of research with focus on primary human brain and kidney endothelial cells.
Legros N; Pohlentz G; Steil D; Müthing J
Int J Med Microbiol; 2018 Dec; 308(8):1073-1084. PubMed ID: 30224239
[TBL] [Abstract][Full Text] [Related]
28. Virulence profiles of Shiga toxin 2e-producing Escherichia coli isolated from healthy pig at slaughter.
Zweifel C; Schumacher S; Beutin L; Blanco J; Stephan R
Vet Microbiol; 2006 Oct; 117(2-4):328-32. PubMed ID: 16872761
[TBL] [Abstract][Full Text] [Related]
29. Characteristics of O157 versus non-O157 Shiga toxin-producing Escherichia coli infections in Minnesota, 2000-2006.
Hedican EB; Medus C; Besser JM; Juni BA; Koziol B; Taylor C; Smith KE
Clin Infect Dis; 2009 Aug; 49(3):358-64. PubMed ID: 19548834
[TBL] [Abstract][Full Text] [Related]
30. Shiga toxin binding to isolated porcine tissues and peripheral blood leukocytes.
Winter KR; Stoffregen WC; Dean-Nystrom EA
Infect Immun; 2004 Nov; 72(11):6680-4. PubMed ID: 15501802
[TBL] [Abstract][Full Text] [Related]
31. Bovine immune response to shiga-toxigenic Escherichia coli O157:H7.
Hoffman MA; Menge C; Casey TA; Laegreid W; Bosworth BT; Dean-Nystrom EA
Clin Vaccine Immunol; 2006 Dec; 13(12):1322-7. PubMed ID: 17050743
[TBL] [Abstract][Full Text] [Related]
32. Lipopolysaccharide upregulates renal shiga toxin receptors in a primate model of hemolytic uremic syndrome.
Clayton F; Pysher TJ; Lou R; Kohan DE; Denkers ND; Tesh VL; Taylor FB; Siegler RL
Am J Nephrol; 2005; 25(6):536-40. PubMed ID: 16179829
[TBL] [Abstract][Full Text] [Related]
33. Shiga toxin-negative attaching and effacing Escherichia coli: distinct clinical associations with bacterial phylogeny and virulence traits and inferred in-host pathogen evolution.
Bielaszewska M; Middendorf B; Köck R; Friedrich AW; Fruth A; Karch H; Schmidt MA; Mellmann A
Clin Infect Dis; 2008 Jul; 47(2):208-17. PubMed ID: 18564929
[TBL] [Abstract][Full Text] [Related]
34. Thalamic involvement in patients with neurologic impairment due to Shiga toxin 2.
Meuth SG; Göbel K; Kanyshkova T; Ehling P; Ritter MA; Schwindt W; Bielaszewska M; Lebiedz P; Coulon P; Herrmann AM; Storck W; Kohmann D; Müthing J; Pavenstädt H; Kuhlmann T; Karch H; Peters G; Budde T; Wiendl H; Pape HC
Ann Neurol; 2013 Mar; 73(3):419-29. PubMed ID: 23424019
[TBL] [Abstract][Full Text] [Related]
35. [Cytotoxic effect of Shiga toxin type 2 and its B subunit on human renal tubular epithelial cell cultures].
Creydt VP; Nuñez P; Zotta E; Ibarra C
Medicina (B Aires); 2005; 65(2):147-50. PubMed ID: 16075810
[TBL] [Abstract][Full Text] [Related]
36. [Hemolytic uremic syndrome caused by enterohaemorrhagic Escherichia coli].
Ibarra C; Goldstein J; Silberstein C; Zotta E; Belardo M; Repetto HA
Arch Argent Pediatr; 2008 Oct; 106(5):435-42. PubMed ID: 19030644
[TBL] [Abstract][Full Text] [Related]
37. Fabry disease in mice protects against lethal disease caused by Shiga toxin-expressing enterohemorrhagic Escherichia coli.
Cilmi SA; Karalius BJ; Choy W; Smith RN; Butterton JR
J Infect Dis; 2006 Oct; 194(8):1135-40. PubMed ID: 16991089
[TBL] [Abstract][Full Text] [Related]
38. [Effect of cytokines on the expression of Shiga toxin toxicity].
Nakane A; Sasaki S
Nihon Rinsho; 2002 Jun; 60(6):1089-94. PubMed ID: 12078078
[TBL] [Abstract][Full Text] [Related]
39. Environmental Cues Modulate Microglial Cell Behavior Upon Shiga Toxin 2 From Enterohemorrhagic
Berdasco C; Duhalde Vega M; Rosato-Siri MV; Goldstein J
Front Cell Infect Microbiol; 2019; 9():442. PubMed ID: 31970091
[TBL] [Abstract][Full Text] [Related]
40. Exosomes released from Shiga toxin 2a-treated human macrophages modulate inflammatory responses and induce cell death in toxin receptor expressing human cells.
Lee KS; Lee J; Lee P; Kim CU; Kim DJ; Jeong YJ; Park YJ; Tesh VL; Lee MS
Cell Microbiol; 2020 Nov; 22(11):e13249. PubMed ID: 32772454
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
